Accedi
Accedi
Oppure accedi con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registrati
Oppure accedi con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

I Leader della Finanza

HomeTutte le notizieLe notizie pi¨ letteBiografie dei Leader della finanza 
Portrait de Gil S. Omenn
EtÓ : 80
Patrimonio pubblico : 272 015 USD
Principali societÓ : Galectin Therapeutics Inc. - Angion Biomedica Corp. - Amesite Inc.
Riassunto 
Gil S. Omenn is Member-Community Preventive Services Task Force at Centers for Disease Control & Prevention, Member of American Academy of Arts & Sciences, Member of National Academy of Medicine (United States), Member of Association of American Physicians and Vice President at Human Proteome Organization and on the board of 11 other companies.

Dr. Omenn previously held the position of Chief Executive Officer of University of Miami Health System, Advisor at Arboretum Ventures, Inc., Associate Director at Office of Management & Budget, Associate Director at White House Office of Science & Technology Policy, Chairman at tranSMART Foundation, Member-Scientific Management Review at National Institutes of Health, Associate Director at Office of Science & Technology Policy, Member of American College of Physicians, Inc., Chief Executive Officer at Michigan Medicine, President at American Association for the Advancement of Science, Executive VP-Medical Affairs & Professor at the University of Michigan, Professor at the University of Washington, Affiliate Faculty at Institute for Systems Biology, Council Member at National Academy of Medicine (United States) and Member of Fred Hutchinson Cancer Research Center.

Gil S. Omenn received a doctorate from the University of Washington, a doctorate from Harvard Medical School and an undergraduate degree from Princeton University.


Posti e reponsabilitÓ di Gil S. Omenn 
NomeTitolo Da
Galectin Therapeutics Inc.
(Biotecnologia)
Independent Director 2014
Angion Biomedica Corp.
(Biotecnologia)
Independent Director 2020
Amesite Inc.
(Software)
Independent Director 2020
Armune BioScience, Inc. Director 2008
Population Services International Director -
Salzburg Global Seminar, Inc. Director -
The CNA Corp. Trustee -
The Center for Public Integrity Director -
The Hastings Center Director -
Life Sciences Society Director -
Phenomics Health, Inc. Director -
Centers for Disease Control & Prevention Member-Community Preventive Services Task Force -
American Academy of Arts & Sciences Member -
National Academy of Medicine (United States) Member -
Association of American Physicians Member -
Human Proteome Organization Vice President 2011


Participazioni di Gil S. Omenn 
NomeAzioni%Valorizzazione
Angion Biomedica Corp. (ANGN)
(Biotecnologia)
141 9830,47%115 290 USD
Galectin Therapeutics Inc. (GALT)
(Biotecnologia)
82 2400,14%92 931 USD
PRO PHARMACEUTICALS INC PFD SER A50 0003,57%56 500 USD
Amesite Inc. (AMST)
(Software)
41 6660,14%7 292 USD
Amesite, Inc.155 7900,96%2 USD


Gil S. Omenn: network personale 
Le notizie pi¨ lette 
13/01L'investitore Peltz, medico aziendale, spinge Disney a prendere la pillola amara
MR
26/01Musk dice che i rivali cinesi "lavorano in modo più duro e intelligente".
MR
26/01Arnault di LVMH respinge la questione della successione
MR
13/01Musk scommette molto sulla possibilità di battere gli azionisti nel processo di 'finanziamento assicurato'.
MR
27/01Bill Ackman dice che il rapporto di Hindenburg su Adani Group è 'altamente credibile'.
MR
27/01L'ARK Innovation Fund di Wood è al passo con il miglior mese di sempre, grazie all'impennata dei titoli azionari
MR
19/01Il CEO di JPMorgan Dimon vede i tassi di interesse andare oltre il 5% - CNBC
MR
19/01I lavoratori GM licenziati in India fanno causa all'azienda e al CEO Barra per il risarcimento non pagato
MR
20/01Musk è atteso al banco dei testimoni alla ripresa del processo per il tweet di Tesla
MR
18/01Il CEO di Takeaway Groen: il processo di vendita di Grubhub è 'difficile', visto l'attuale mercato delle fusioni e acquisizioni.
MR
Altre news


© 2023 People and Ownership :   
Gil S. Omenn : connessioni